A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma-Reference-Cited by-同舟云学术

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma

Published:2019-08-14 Issue:4 Volume:38 Page:1056-1066
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Takahashi Shunji,Uemura Motohide,Kimura Tomokazu,Kawasaki Yoshihide,Takamoto Atsushi,Yamaguchi Akito,Melhem-Bertrandt Amal,Gartner Elaina M.,Inoue Takashi,Akazawa Rio,Kadokura Takeshi,Tanikawa Toshiki

Funder

Astellas Pharma, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00844-x.pdf

Reference15 articles.

1. Bharmal M, Guenther S, Kearney M, Kempel-Waibel A (2017) Epidemiology of locally advanced or metastatic urothelial cancer in the US, Europe and Japan. Value in health 20:Abstract PCN45.

2. Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A, European Association of U (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65(4):778–792. https://doi.org/10.1016/j.eururo.2013.11.046

3. Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT (2016) Guideline on muscle-invasive and metastatic bladder cancer (European association of urology guideline): American society of clinical oncology clinical practice guideline endorsement. J Clin Oncol 34(16):1945–1952. https://doi.org/10.1200/JCO.2015.65.9797

4. De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, Collette S, Lorent J, de Wit R, Sylvester R (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191–199. https://doi.org/10.1200/JCO.2011.37.3571

5. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, Investigators K (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives;International Journal of Molecular Sciences;2024-09-07

2. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer;Cancers;2024-09-04

3. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

4. Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma;Clinical Pharmacology & Therapeutics;2024-07-22

5. Efficacy and safety of antibody–drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials;Frontiers in Pharmacology;2024-06-12